Regeneron’s evinacumab gets FDA breakthrough therapy status to treat HoFH

This article was originally published here

Regeneron Pharmaceuticals has secured breakthrough therapy status from the US Food and Drug Administration (FDA) for its evinacumab to treat patients with homozygous familial hypercholesterolemia (HoFH).

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply